Technology evaluation: PROSTVAC, Therion.
Therion Biologics is developing PROSTVAC, an immunotherapeutic vaccine that targets prostate-specific antigen, for the potential treatment of prostate cancer. In February 2000, phase II trials had commenced. By October 2001, the drug was undergoing four phase II trials.
Doehn
Christian
C
Department of Urology, University of Lübeck Medial School, Germany. doehn@medinf.mu-luebeck.de
Jocham
Dieter
D
D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D013673:Technology Assessment, Biomedical
D019496:Cancer Vaccines